li001

The Phase 3 EMERALD-3 trial found that adding immunotherapy to standard treatment significantly delayed disease progression in patients with unresectable hepatocellular carcinoma (HCC) eligible for transarterial chemoembolization (TACE). The study enrolled 760 patients and compared STRIDE immunotherapy (tremelimumab plus durvalumab) combined with lenvatinib and TACE, STRIDE plus TACE, and TACE alone. Patients receiving the full combination

A clinical trial involving 500 patients has shown that the daily oral drug daraxonrasib may significantly extend survival in advanced pancreatic cancer, an outcome researchers are describing as a major breakthrough. In the study presented at the American Society of Clinical Oncology annual meeting, patients receiving daraxonrasib lived a median of 13.2 months, compared with

The phase 3 BREAKWATER trial  shows that a targeted combination of encorafenib (Braftovi), cetuximab (Erbitux), and FOLFIRI chemotherapy significantly improves outcomes for patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer. The regimen is now considered a new standard of care following FDA traditional approval in February 2026. The study enrolled 147 patients and compared

Abemaciclib (Verzenio) has shown the first positive phase 3 trial result in advanced or metastatic dedifferentiated liposarcoma (DDLS), according to the SARC041 study. The oral CDK4/6 inhibitor significantly delayed disease progression compared with placebo in a cancer type with very limited treatment options. The trial enrolled 108 patients with progressive, recurrent, or metastatic DDLS randomized

The phase 3 frontMIND trial has demonstrated that adding tafasitamab (Monjuvi) and lenalidomide (Revlimid) to standard R-CHOP chemotherapy improves outcomes for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL). After a median follow-up of 35.2 months, the combination reduced the risk of disease progression or death by 25% compared with R-CHOP alone. Two-year

Daraxonrasib (RMC-6236) delivered breakthrough results in the phase 3 RASolute 302 trial offering a major advance for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The study enrolled 500 patients whose cancer had progressed after one prior chemotherapy regimen and compared oral daraxonrasib with standard chemotherapy options. Patients treated with daraxonrasib achieved a median overall

A phase 3 trial showed that the TMC-I regimen significantly improved survival in patients with platinum-sensitive, advanced head and neck squamous cell carcinoma receiving first-line palliative treatment. Conducted at the Tata Memorial Centre in India, the study compared TMC-I—an oral combination of methotrexate, erlotinib, and celecoxib plus ultra-low-dose nivolumab—with standard paclitaxel-carboplatin chemotherapy in 422 patients.